EPO and myocardial infarction: The therapeutic relevance of EPO in the clinical setting of cardiovascular diseases has been confirmed by studies in which EPO treatment was started 3 or 6 weeks after induction of myocardial infarction, when heart failure was fully established in mice [31,32].